Summary
Sixteen patients treated with cisplatin (CDDP) 40 mg/m2 on days 1–5 every 4 weeks for three courses (cumulative dose 600 mg/m2) were clinically and neurophysiologically tested before, during and 1, 3, 6, 9 and 12 months after CDDP administration. The first symptoms of polyneuropathy occurred in 4 of 9 patients after the second course (cumulative dose 400 mg/m2). One month after treatment 1 of 9 patients was asymptomatic, 5 complained of symptoms and 3 showed clinical and neurophysiological signs of polyneuropathy. Three months after CDDP all patients were affected. Clinical and neurophysiological signs of severity progression were noted up to 6 months after treatment with CDDP.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Argov Z, Mastaglia F (1979) Drug-induced peripheral neuropathies. BMJ 1:663–666
Arnold AM, Williams CJ (1979) Drug-induced peripheral neuropathies. BMJ 1:955
Ashraf M, Scotchel PL, Krall RNJM, Flink EB (1983) Cisplatinum induced hypomagnesemia and peripheral neuropathy. Gynecol Oncol 16:309–318
Becher R, Shutt P, Osieka R, Schmidt CG (1980) Peripheral neuropathy and ophthalmologic toxicity after treatment with cisdichlorodiaminoplatinum II. J Cancer Res Clin Oncol 96:219–221
Berman IJ, Mann MP (1980) Seizures and transient cortical blindness associated with cis-platinum (II) diammine-dichloride (PDD) therapy in a thirty year old man. Cancer 45:764–766
Cavanagh JB (1986) Sensorymotor neuropathy and adriamycin toxicity. J Neurol Neurosurg Psychiatry 49:964–965
Cowan JD, Kies MS, Roth JL, Joice RP (1980) Nerve conduction studies in patients treated with cis-diammine-dichloroplatinum (II): a preliminary report. Cancer Treat Rep 64:1119–1122
Daugaard GK, Petrera J, Trojaborg W (1987) Electrophysiological study of the peripheral and central neurotoxic effect of cis-platin. Acta Neurol Scand 76:86–93
Dewar J, Lunt H, Abernethy DA, Dady P, Haas LF (1986) Cisplatin neuropathy with Lhermitte's sign. J Neurol Neurosurg Psychiatry 49:96–99
Gastaut JL, Pellissier JF (1985) Neuropathie au cisplatine étude clinique, electrophysiologique et morphologique. Rev Neurol (Paris) 141:614–626
Hansen SW, Helweg-Larsen S, Trojaborg W (1989) Long-term neurotoxicity with cisplatin, vinblastine, and bleomycin for metastatic germ cell cancer. J Clin Oncol 7:1457–1461
Kaplan RS, Wiernik PH (1982) Neurotoxicity of antineoplastic drugs. Semin Oncol 9:103–130
Mollman JE, Hogan WM, Glover DJ, McCluskey LF (1988) Unusual presentation of cis-platinum neuropathy. Neurology 38:488–490
Mollman JE, Glover DJ, Hogan WM, Furman RE (1988) Cisplatin neuropathy. Cancer 61:2192–2195
Ongerboer de Visser BW, Tiessens G (1985) Polyneuropathy induced by cisplatin. Prog Exp Tumor Res 29:190–196
Ostrow S, Hahn D, Wiernik PH, Richards RD (1978) Ophthalmologic toxicity after cis-dichlorodiammineplatinum (II) therapy. Cancer Treat Rep 62:1591–1594
Pages M, Pages AM, Bories-Azeau L (1986) Severe sensory-motor neuropathy after cisplatin therapy. J Neurol Neurosurg Psychiatry 49:333–334
Riggs JE, Ashraf M, Snyder RD, Gutmann L (1988) Prospective nerve conduction studies in cisplatin therapy. Ann Neurol 23:92–94
Roelofs RI, Hrashesky W, Rogin J, Rosenberg L (1984) Peripheral sensory neuropathy and cisplatin chemotherapy. Neurology 34:934–938
Roth BJ, Greist A, Kubilis PS, Williams SD, Einhorn LH (1988) Cisplatin-based combination chemotherapy for disseminated germ cell tumors: long-term follow-up. J Clin Oncol 6:1239–1247
Thompson SW, Davis LAE, Kornfeld M, Hilgers RD, Standefer JC (1984) Cisplatin neuropathy. Clinical, electrophysiologic, morphologic, and toxicologic studies. Cancer 54:1269–1275
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
LoMonaco, M., Milone, M., Batocchi, A.P. et al. Cisplatin neuropathy: clinical course and neurophysiological findings. J Neurol 239, 199–204 (1992). https://doi.org/10.1007/BF00839140
Received:
Revised:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00839140